The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer (DRPC).
Christoph W. Reuter
No relevant relationships to disclose
Michael A. Morgan
No relevant relationships to disclose
Viktor Gruenwald
No relevant relationships to disclose
Martin Fenner
No relevant relationships to disclose
Philipp Ivanyi
No relevant relationships to disclose
Arnold Ganser
No relevant relationships to disclose